Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.

Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R

The Journal of clinical endocrinology and metabolism1 Nov 2003Cited by 138 (Europe PMC)

PMID14602752DOI10.1210/jc.2003-030768PepBankPUB-14602752

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, PTH induced time- and dose-related increases in lumbar spine BMD.
In plain wordsIn osteoporotic women, spine bone density increased with PTH dose and time.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine BMD dose and time response
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50, 75, or 100 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
PTH treatment induced time- and dose-related increases in lumbar spine bone mineral density (BMD).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275201
02HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, PTH increased BMD significantly by 2.0% at 3 months.
In plain wordsIn osteoporotic women, spine bone density increased from baseline with PTH at 3 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine BMD at 3 months
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change
2%
100-microg dose, 3 months
Source sentences
Summary
The 100-microg dose increased BMD significantly at 3 months (+2.0%) and 12 months (+7.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275202
03HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, PTH increased BMD significantly by 7.8% at 12 months.
In plain wordsIn osteoporotic women, spine bone density increased from baseline with PTH at 12 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine BMD at 12 months
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change
7.8%
100-microg dose, 12 months
Source sentences
Summary
The 100-microg dose increased BMD significantly at 3 months (+2.0%) and 12 months (+7.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275203
04HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, lumbar spine bone mineral content increased by 10.0% during PTH treatment.
In plain wordsIn osteoporotic women, lumbar spine bone mineral content increased during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine bone mineral content
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Lumbar spine bone mineral content change
10%
lumbar spine
Source sentences
Summary
BMD underestimated the anabolic effect of PTH in lumbar spine (bone mineral content, +10.0%) because bone area increased significantly (+2.0%).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275204
05HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, lumbar spine bone area increased significantly by 2.0% during PTH treatment.
In plain wordsIn osteoporotic women, lumbar spine bone area increased during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine bone area
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Lumbar spine bone area change
2%
lumbar spine
Source sentences
Summary
BMD underestimated the anabolic effect of PTH in lumbar spine (bone mineral content, +10.0%) because bone area increased significantly (+2.0%).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275205
06HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, total hip BMD decreased nonsignificantly by 0.9% during the first 6 months of PTH.
In plain wordsIn osteoporotic women, hip bone density decreased slightly during early PTH treatment, without statistical significance.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseTotal hip BMD in first 6 months
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Total hip BMD change
−0.9%
100-microg dose, first 6 months
Source sentences
Summary
A nonsignificant decrease (-0.9%) in total hip BMD occurred during the first 6 months with the 100-microg dose, but this trend reversed (+1.6%) during the second 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275206
07HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, the hip BMD trend reversed to +1.6% during the second 6 months of PTH treatment.
In plain wordsIn osteoporotic women, the hip bone density trend reversed upward during the second half of PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseTotal hip BMD in second 6 months
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · subcutaneousAs given in this study (human).
Measurements
Total hip BMD change
1.6%
100-microg dose, second 6 months
Source sentences
Summary
A nonsignificant decrease (-0.9%) in total hip BMD occurred during the first 6 months with the 100-microg dose, but this trend reversed (+1.6%) during the second 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275207
08HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, turnover markers increased during early PTH treatment and remained elevated during the second 6 months.
In plain wordsIn osteoporotic women, bone turnover markers increased during PTH treatment and remained elevated.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseBone turnover markers
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50, 75, or 100 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Bone turnover markers increased during the first half of the study and were maintained at elevated levels during the second 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275208
09HumanNon-randomized trialSafety outcome
In osteoporotic postmenopausal women, PTH treatment was generally safe and well tolerated.
In plain wordsIn osteoporotic women, PTH treatment was generally well tolerated.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Not applicableGeneral tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
50, 75, or 100 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Protocol compliance was excellent (95-98%), and treatment was generally safe and well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275209
10HumanNon-randomized trialSafety outcome
In osteoporotic postmenopausal women, transient hypercalcemia occurred with dose-related incidence during PTH treatment.
In plain wordsIn osteoporotic women, transient high blood calcium occurred more often at higher PTH doses.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseTransient hypercalcemia
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
50, 75, or 100 microg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Dose-related incidences of transient hypercalcemia occurred, but only one patient (100-microg group) was withdrawn because of repeated hypercalcemia.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275210
11HumanNon-randomized trialSafety outcome
In osteoporotic postmenopausal women, one patient in the highest-dose PTH group withdrew because of repeated hypercalcemia.
In plain wordsIn osteoporotic women, one patient receiving the highest PTH dose withdrew because of repeated high blood calcium.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Not applicableWithdrawal for repeated hypercalcemia
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
100 microg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Dose-related incidences of transient hypercalcemia occurred, but only one patient (100-microg group) was withdrawn because of repeated hypercalcemia.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the efficacy and safety of human PTH-(1-84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study.
Summary · context
The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.
Report a problemFND-1460275211

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.